Tim Lohoff, PhD, Principal at Forbion, will join Protego’s Board of Directors
Naarden, The Netherlands - Dec. 1, 2025 - Forbion, a leading life sciences venture capital firm with deep roots in Europe, today announces that it has co-led an over-subscribed $130 million Series B financing in Protego Biopharma, Inc., a clinical-stage biotechnology company dedicated to pioneering first-in-class small molecule therapeutics that reprogram protein folding to address systemic amyloid diseases and other protein misfolding disorders.
Proceeds will advance Protego’s lead candidate, PROT-001, into a pivotal clinical trial for AL amyloidosis, a rare and often fatal condition caused by protein misfolding that leads to organ damage, especially in the heart.
Protego is advancing a highly differentiated approach with the potential to transform treatment for patients with AL amyloidosis. By targeting the root cause of this severe disease, PROT-001 has the potential to deliver the first truly disease-modifying therapy in this indication. At Forbion, we invest in bold teams turning breakthrough science into tangible medical and commercial impact, and Protego exemplifies that vision.
Tim Lohoff, PhD, Principal
Principal, Forbion
"We are deeply grateful for the steadfast support of our existing investors, who have believed in us through every stage, and we are pleased to welcome leading global investors to join us on this journey. Their confidence underscores the promise of our science and the urgency of our mission," said Brent Warner, Chief Executive Officer of Protego Biopharma. "With the capital raised, we are positioned to advance PROT-001 into pivotal trials, moving closer to delivering the first disease-modifying therapy for AL amyloidosis and offering new hope to patients who currently face devastating outcomes."
Protego’s therapeutic strategy is rooted in human genetics and a unique pharmacological chaperone mechanism. These small molecules act as cellular “guides,” ensuring proteins fold correctly. By stabilizing immunoglobulin light chains and preventing amyloid buildup, PROT-001 addresses disease at its root cause rather than simply managing symptoms. This approach represents a potential paradigm shift not only for AL amyloidosis, but also for a wide spectrum of protein misfolding disorders with profound unmet needs.
Read the company release here.
***ENDS***
About Protego Biopharma
Protego Biopharma is a San Diego-based biotech company focused on developing small-molecule drugs that target protein misfolding pathways. By reprogramming cellular processes to restore proper protein function, Protego aims to treat rare and systemic diseases with precision and improved patient outcomes. For more information, visit www.protegobio.com.
